Clinical Trial

A Multicenter, Prospective, Randomized, Controlled Study of Decitabine in Combination With R-CHOP for Initial Treatment of EBV+ Diffuse Large B-cell Lymphoma

Enrolling by Invitation Phase 3

Record status

This record was last updated January 16, 2026 (before its estimated July 1, 2026 completion). Its status may not reflect the trial's current state.

Summary

This trial was a prospective, multicenter, randomized, controlled Phase III clinical design to compare the efficacy and safety of decitabine combined with R-CHOP (R-CHOP-D) versus R-CHOP in the treatment of primary EBV+ diffuse large B-cell lymphoma (DLBCL). Sixty patients were randomized 1:1 into R-CHOP-D (trial group) or R-CHOP (control group). The trial consisted of a screening period (days -28 to -1), a treatment period, and a follow-up period (2 years after the end of the last trial).

Trial Details

NCT Number	NCT07348575
Lead Sponsor	Second Affiliated Hospital of Nanchang University
Conditions	Lymphoma, Large-Cell, Diffuse
Enrollment	80 participants
Start Date	2024-07-01
Primary Completion	2026-07-01 (estimated)
Study Completion	2028-07-01 (estimated)
Updated on ClinicalTrials.gov	2026-01-16